ECPO Files Issuers Company Related Action Notification with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
63
ECPO Files Issuers Company Related Action Notification with the Financial Industry Regulatory Authority requesting Name and Symbol Change

MONROVIA, CA--(Marketwired - Jul 20, 2017) -  Eco Petroleum Solutions, Inc. (OTC PINK: ECPO) (the "Company") announces that it has completed and filed the Issuers Company Related Action Notification requesting, because of the recent share exchange transaction, that the Company's name be changed to Immunotech Laboratories, Inc. to more accurately reflect ECPO's entry into the Immunotherapy Treatment Market. Amendments to the articles of Incorporation were filed with the State of Delaware the week of July 10th.

The Company updated the progress on the initial validation order of 10,000 vials and the related documentation required for the issuance of the permit for mass production and sale. The production has been scheduled to begin in mid-September. The validation order will be completed in batches of 3,300+/- and the necessary documentation to complete the registration process will be delivered to the Bulgarian Drug Agency (BDA) during the manufacturing process. Upon successful completion of the validation and review of the resulting documentation by the BDA the issuance of the permit will allow the treatment to be sold wherever the permit issued by the BDA is recognized, including the Ukraine and other Eastern European countries. The Company expects additional orders to be placed in similar quantities on a monthly basis after the issuance of the permit under the existing Ukraine distribution agreement. Other distribution agreements are currently being negotiated.

"In 2015 there were approximately 2.1 million new HIV/AIDS infections or about 5,700 infections per day. This equates to 4 new infections per minute of which statistically 51% of the newly infected are women and a third of the new carriers are between the ages of 15 and 24 years old. Half of the individuals infected with the virus do not know they have the disease. Since the mid-1990s there has been significant decreases in new infections, it is concerning that new infections among adults has failed to decline over the past 5 years and the incidence of new adult infections are rising in some regions," stated Harry Zhabilov, CEO of ECPO/Immunotech Laboratories, Inc. "We believe that when our treatment for this deadly disease is finally approved for mass production and sale the world will not only reap the benefit of helping treat the infected population, giving the individuals a chance at a more productive and fulfilling life, but also stem the cost of the disease in dollars spent on treatment and related expenses incurred because of HIV/AIDS."

About Immunotech: Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.

Immunotech's flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Eco Petroleum Solutions, Inc. / Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.

While Eco Petroleum / Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Eco Petroleum / Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests.

Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Eco Petroleum / Immunotech Laboratories or any other person that the objectives and plans of Eco Petroleum / Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

IR Contact: Immunotech Laboratories, Inc. 120 W Pomona Ave Monrovia, CA 91016 Phone: (626) 538-4779 Fax: (626) 538-4779

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 54

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 250

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 106

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 82

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 176

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 0

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Marjorie Taylor Greene's Diverse Portfolio Emphasizes Growth

Updated Category News Views 243

Marjorie Taylor Greene's Investment Choices Marjorie Taylor Greene, a well-known congressional representative, is making headlines lately with her recent stock investments. Reports indicate that her investment decisions reflect a strong interest in diverse sectors, including technology, healthcare, and logistics. This varied approach highlights her strategic thinking as...

Continue Reading
RBB Bancorp's Incredible Third Quarter Gains and Dividend

Updated Category News Views 178

RBB Bancorp: A Review of Stellar Financial Performance RBB Bancorp, alongside its subsidiaries, has recently announced impressive financial results for the quarter ended September 30, 2025. In an era where financial stability is paramount, RBB Bancorp (NASDAQ:RBB) emerged with promising metrics indicating solid progress. Key Financial Highlights for Q3 2025 Net income...

Continue Reading
Hancock Whitney to Share Q3 2024 Results and Insights Soon

Updated Category News Views 69

Exciting News from Hancock Whitney Corporation Hancock Whitney Corporation (Nasdaq: HWC) is about to share its financial performance for the third quarter of 2024. This announcement will take place after the market closes, paving the way for an insightful conference call with both analysts and investors. Details on Financial Results and Conference Call The expected...

Continue Reading
GunsAmerica Reinforces Leading Role in Safe Online Firearm Sales

Updated Category News Views 229

GunsAmerica Reinforces Leading Role in Safe Online Firearm Sales GunsAmerica stands at the forefront of the online firearm marketplace, continually evolving to ensure the utmost safety and security for its users. The platform has earned a stellar reputation over its impressive 28-year history by prioritizing secure firearm transactions and implementing robust measures...

Continue Reading
Acrivon Therapeutics Pushes Ahead with ACR-2316 Trials

Updated Category News Views 70

Exciting Milestone in Oncology Trials Acrivon Therapeutics, Inc. has recently reached a significant milestone by dosing its first patient in the Phase 1 clinical trial of ACR-2316. This innovative WEE1/PKMYT1 inhibitor was developed using Acrivon’s advanced AP3 platform, which accelerates the discovery and design of effective cancer treatments. The progress marks a...

Continue Reading